Know what’s really happening at
Ollin Biosciences before you sign on.
- On the roadmap
- Ophthalmology
- Biopharmaceutical
- Drug Development
Ollin Biosciences is a clinical-stage biopharmaceutical company developing bispecific antibody therapies for vision-threatening eye diseases including wet AMD, DME, and thyroid eye disease. Founded in 2023 and already valued at over $1 billion, the Austin-based company has attracted a heavyweight investor syndicate and is advancing two differentiated programs toward later-stage trials.
How we do it.
Most "AI market intel" is a summarized crawl of press releases. This Altis research is built from our knowledge graph of sector expert calls, synthesized with public sources.
Ollin Biosciences
- Series B Raised (June 2026)
- $330M
- Total Funding
- $430M
- Reported Valuation
- $1.3B
- Year Founded
- 2023
- Company Size
- 11-50
- Headquarters
- Austin, Texas, United States
- Funding Rounds
- 2
Press reported
Altis Verified
What's in the report
Most "AI market intel" is a summarized crawl of press releases. This is what customers, competitors, and former employees actually told us.
Market Overview
Market structure, where the company sits, and growth drivers.
- market map
- Ophthalmology landscape
- Ophthalmology growth rate
- CAGR
Total Addressable Market
Bottom-up TAM / SAM / SOM.
- Ollin Biosciences TAM
- Ophthalmology market size
- market opportunity
Company Overview
What the company does and how it operates.
- what does Ollin Biosciences do
- Ollin Biosciences product
- business model
Product / Go-to-Market
Product, GTM motion, ICP, and who buys.
- Ollin Biosciences customers
- who uses Ollin Biosciences
- Ollin Biosciences ICP
- go-to-market
Competitive Dynamics
The Altis Market Map and the Altis Win-Rate Index.
- Ollin Biosciences competitors
- Ollin Biosciences alternatives
- who competes with Ollin Biosciences
- Ollin Biosciences win rate
Customer Signals
Retention, satisfaction, and win/loss signals.
- Ollin Biosciences reviews
- Ollin Biosciences NRR
- Ollin Biosciences churn
- current customers
- switching costs
Investment Debates
Investment thesis, moat, bull/bear, and key risks.
- Ollin Biosciences investment thesis
- Ollin Biosciences moat
- bull case bear case
- Ollin Biosciences risk factors
Monetization & Financials
Business model, revenue model, and unit economics.
- Ollin Biosciences ARR
- Ollin Biosciences revenue
- Ollin Biosciences valuation
- unit economics
Team and culture
Founders, leadership, and org.
- Ollin Biosciences founders
- Ollin Biosciences CEO background
- leadership team
- headcount
Trusted by
Ready to see the full picture?
Profile based on structured company data, public funding records, and investor disclosures as of July 2026.